Oral Absorption and Pharmacokinetics of Rebamipide and Rebamipide Lysinate in Rats

College of Pharmacy, Sungkyunkwan University, Suwon, Kyeonggi-do, Korea.
Drug Development and Industrial Pharmacy (Impact Factor: 2.1). 10/2004; 30(8):869-76. DOI: 10.1081/DDC-200034577
Source: PubMed

ABSTRACT Rebamipide is an anti-ulcer agent exhibiting a low aqueous solubility and a poor oral bioavailability. This study was conducted to examine if the rebamipide lysinate salt form would exhibit improved solubility profiles and higher oral bioavailability compared with rebamipide free acid. Both compounds showed pH-dependent solubility profiles, with the solubility of rebamipide lysinate dramatically improved at a median pH of 5.1 (17-fold increases) over free acid, but the improvement in the solubility was not as pronounced in artificial gastric and intestinal fluids (1.4- and 1.9-fold increases, respectively). The Cl, V(ss) and t1/2 in rats after i.v. injection of rebamipide (0.5 mg/kg) averaged 21.0 +/- 3.2 ml/min/kg, 0.3 +/- 0.0 L/kg, and 0.4 +/- 0.1 hr, respectively. No significant difference was observed in these parameters between rebamipide and rebamipide lysinate. Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid. Rebamipide lysinate, however, showed a more rapid absorption, and initial serum drug concentrations were higher than those found for rebamipide free acid.

104 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to compare the pharmacokinetic parameters of zaltoprofen and those of its sodium salt in rats. Zaltoprofen, a potent non-steroidal anti-inflammatory agent, was virtually insoluble in water, but its sodium salt had excellent water solubility. To investigate the effect of aqueous solubility differences upon their pharmacokinetic parameters, minicapsules containing the drug powders were administrated orally to rats, and blood samples were taken via the common carotid artery. A column-switching high-performance liquid chromatographic analytical procedure was developed and validated for the quantitation of zaltoprofen in rat plasma samples. Our study demonstrated that the time required to reach maximum plasma concentration (T(max)) of zaltoprofen sodium was significantly reduced and its maximum plasma concentration (C(max)) was increased 1.5-fold, relative to the values for zaltoprofen. It is anticipated that the sodium salt of zaltoprofen will allow the rapid onset of the drug's action in the treatment of inflammatory diseases.
    Biomedical Chromatography 05/2009; 23(5):537-42. DOI:10.1002/bmc.1151 · 1.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rebamipide is a quinolinone-derived gastroprotective agent approved in Korea for the treatment of gastric ulcers, acute gastritis, and exacerbated chronic gastritis. The aims of this study were to evaluate the pharmacokinetics and bioequivalence of a reference (branded) and test (generic) formulation of rebamipide 100-mg tablets in healthy Korean male volunteers for the purposes of generic substitution and to evaluate the relationship between genetic polymorphisms in the ABCB1 gene (exons 21 and 26) and rebamipide pharmacokinetics. This study had a 2-period crossover design, with a 7-day washout between formulations. Healthy Korean male volunteers were randomly assigned to receive a single 100-mg dose of the test or reference formulation, administered with 240 mL of water after a 12-hour overnight fast. Serum concentrations of rebamipide up to 12 hours after administration were determined using a validated HPLC method with fluorescence detection. Vital signs (temperature, blood pressure, and heart rate) were measured before and after dosing in both periods. Adverse events were monitored by clinic staff on the days of study drug administration and were recorded for up to 1 week after the last dose of study medication. Pharmacokinetic parameters were determined using a noncompartmental method. The formulations were considered bioequivalent if the log-transformed ratios of AUC(0-t), AUC(0-infinity)), and C(max) were within the predetermined bioequivalence range (80%-125%) established by the US Food and Drug Administration and Korean legislation. The in vitro dissolution profiles of the 2 formulations were examined, and the influence on rebamipide pharmacokinetics of genetic polymorphisms in the ABCB1 gene (P-glycoprotein) was investigated. Thirty healthy Korean male volunteers (mean [SD] age, 22.97 [1.67] years [range, 20-27 years]; height, 174.56 [6.27] cm [range, 159.1-184.8 cm]; and weight, 69.44 [8.32] kg [range, 54.7-90.2 kg]) were enrolled in and completed the study. No adverse events were reported. The 2 formulations had comparable in vitro dissolution profiles. The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours. No significant sequence, subject, formulation, or period effects were detected for any pharmacokinetic parameter. The point estimates for AUC(0-t), AUC(0-infinity), and C(max) were 0.95 (90% CI, 0.84-1.06), 0.95 (90% CI, 0.84-1.06), and 1.01 (90% CI, 0.89-1.15), respectively, satisfying the criterion for bioequivalence. There was no statistically significant difference in T(max). No significant differences in rebamipide AUC(0-t), AUC(0-infinity), or C(max) were found among the ABCB1 2677 GG, GT, or TT groups, or among the ABCB1 3435 CC, CT, or TT groups. There was no evidence that genetic polymorphisms in the ABCB1 gene influenced the pharmacokinetics of rebamipide. The results of this study in healthy Korean male volunteers suggest that the 2 rebamipide 100-mg tablet formulations administered in the fasted state met the regulatory criterion for bioequivalence. There was no evidence that rebamipide pharmacokinetic parameters were influenced by genetic polymorphisms in the ABCB1 gene (exons 21 and 26). identifier: .
    Clinical Therapeutics 11/2009; 31(11):2712-21. DOI:10.1016/j.clinthera.2009.11.010 · 2.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A new, rapid sensitive, simple and cost effective UV method was developed for the estimation of Rebamipide in bulk as well as in pharmaceutical formulations. The relative absorbance of Rebamipide was measured in phosphate buffer (pH 7.4) at new wave length (λ max 227). The linearity range was found to be 2.5-12.5 µg/ml with regression, relative absorbance =0.1061X concentration in µg/ml+0.0009 with regression coefficient 0.9997. The method was tested and validated for various parameters as per ICH and USP specification. The detection and quantification limit was found to be 0.73µg/ml and 2.21 µg/ml respectively. The result demonstrates that the developed procedure is accurate, precise and reproducible (relative standard deviation <2.0%). Proposed method is applicable for the estimation of Rebamipide in different dosage forms and results are in good agreement with label claim. Key words: Rebamipide, Phosphate buffer (pH 7.4), λ max 227 nm, U V method. INTRODUCTION: Rebamipide {2-(4-chlorobenzolylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid} (BCS Class IV drug) is an anti ulcer drug used for the treatment of gastric ulcer. It is also an excellent drug for the treatment of dry eye. Its antiulcer activity has been reported as to increase gastric mucosal blood flow and prostaglandin E2 synthesis and secretion of gastric mucus. Oxygen free radicals can be removed to promote inflammation and peptic ulcer healing improvement. Rebamipide belongs to BCS class IV drug. Along with it's poor water solubility it also have poor solubility in most of organic solvents, but it have pH dependent solubility. Because of it's poor solubility profile there is no UV method to estimate the Rebamipide in there routine analysis and from their formulation. Available literature states only HPLC method of estimation of Rebamipide at 280nm [1-3] . Though HPLC method is highly sensitive and accurate but it is time consuming (Processing time) and demands lot of expertise with
    International Journal of PharmTech Research 06/2011; 3(Vol. 3):1270-1274.
Show more